3.88
price down icon0.26%   -0.01
after-market Handel nachbörslich: 3.88
loading
Schlusskurs vom Vortag:
$3.89
Offen:
$3.86
24-Stunden-Volumen:
1.05M
Relative Volume:
0.41
Marktkapitalisierung:
$332.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.95M
KGV:
-4.619
EPS:
-0.84
Netto-Cashflow:
$-33.46M
1W Leistung:
-10.60%
1M Leistung:
-20.33%
6M Leistung:
+30.64%
1J Leistung:
-49.87%
1-Tages-Spanne:
Value
$3.76
$4.0596
1-Wochen-Bereich:
Value
$3.76
$4.495
52-Wochen-Spanne:
Value
$1.61
$9.50

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name
Firmenname
Larimar Therapeutics Inc
Name
Telefon
844-511-9056
Name
Adresse
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Name
Mitarbeiter
65
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-24
Name
Neueste SEC-Einreichungen
Name
LRMR's Discussions on Twitter

Vergleichen Sie LRMR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LRMR
Larimar Therapeutics Inc
3.88 332.95M 0 -36.95M -33.46M -0.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.00 109.11B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
642.25 68.50B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
434.07 60.25B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
826.28 50.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
186.23 40.44B 447.02M -1.18B -868.57M -6.1812

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-29 Eingeleitet Truist Buy
2024-10-16 Eingeleitet Oppenheimer Outperform
2024-10-03 Eingeleitet Wedbush Outperform
2024-10-02 Eingeleitet H.C. Wainwright Buy
2024-09-04 Eingeleitet Robert W. Baird Outperform
2024-04-03 Eingeleitet Leerink Partners Outperform
2023-11-17 Hochstufung Citigroup Neutral → Buy
2022-10-19 Eingeleitet Guggenheim Buy
2022-02-15 Herabstufung William Blair Outperform → Mkt Perform
2021-02-10 Eingeleitet JMP Securities Mkt Outperform
2021-02-01 Eingeleitet William Blair Outperform
Alle ansehen

Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten

pulisher
09:59 AM

Why Larimar Therapeutics Inc. stock is favored by pension fundsWeekly Profit Report & Daily Volume Surge Trade Alerts - newser.com

09:59 AM
pulisher
09:36 AM

Will Larimar Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - newser.com

09:36 AM
pulisher
09:13 AM

What institutional flow reveals about Larimar Therapeutics Inc.July 2025 Catalysts & Smart Allocation Stock Reports - newser.com

09:13 AM
pulisher
09:00 AM

What machine learning models say about Larimar Therapeutics Inc.Earnings Trend Report & Capital Efficient Trade Techniques - newser.com

09:00 AM
pulisher
07:45 AM

How moving averages guide Larimar Therapeutics Inc. tradingTrade Risk Summary & Community Trade Idea Sharing - newser.com

07:45 AM
pulisher
06:04 AM

Why Larimar Therapeutics Inc. (ZA71) stock stays undervaluedSwing Trade & Community Verified Trade Alerts - newser.com

06:04 AM
pulisher
05:16 AM

How geopolitical risks impact Larimar Therapeutics Inc. (ZA71) stockMarket Growth Summary & AI Optimized Trade Strategies - newser.com

05:16 AM
pulisher
02:45 AM

How Larimar Therapeutics Inc. (ZA71) stock behaves in tightening cycles2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com

02:45 AM
pulisher
02:02 AM

Is Larimar Therapeutics Inc. (ZA71) stock positioned for digital growth era2025 Volume Leaders & High Conviction Investment Ideas - newser.com

02:02 AM
pulisher
01:33 AM

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

01:33 AM
pulisher
01:24 AM

Detecting price anomalies in Larimar Therapeutics Inc. with AIWeekly Gains Summary & Fast Exit and Entry Trade Guides - newser.com

01:24 AM
pulisher
Nov 02, 2025

Will Larimar Therapeutics Inc. stock benefit from automationEarnings Beat & AI Enhanced Trading Alerts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Is Larimar Therapeutics Inc. (ZA71) stock worth buying before Fed actionWeekly Stock Recap & AI Enhanced Market Trend Forecasts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Price action breakdown for Larimar Therapeutics Inc.Weekly Gains Summary & Safe Capital Allocation Plans - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Custom watchlist performance reports with Larimar Therapeutics Inc.July 2025 Final Week & Low Drawdown Trading Strategies - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

How Larimar Therapeutics Inc. stock trades during market volatilityPortfolio Return Report & High Yield Equity Trading Tips - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Larimar Therapeutics Inc. stock retracement – recovery analysisPortfolio Growth Summary & Technical Entry and Exit Alerts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Will Larimar Therapeutics Inc. stock gain from lower inflationWeekly Trade Review & Step-by-Step Trade Execution Guides - newser.com

Nov 02, 2025
pulisher
Nov 01, 2025

What makes Larimar Therapeutics Inc. stock attractive to growth fundsJuly 2025 Volume & Reliable Price Breakout Alerts - newser.com

Nov 01, 2025
pulisher
Nov 01, 2025

Pattern recognition hints at Larimar Therapeutics Inc. upsidePortfolio Update Report & Weekly Hot Stock Watchlists - newser.com

Nov 01, 2025
pulisher
Nov 01, 2025

Published on: 2025-11-01 00:49:57 - newser.com

Nov 01, 2025
pulisher
Oct 31, 2025

Multi factor analysis applied to Larimar Therapeutics Inc.July 2025 Chart Watch & Safe Entry Point Identification - newser.com

Oct 31, 2025
pulisher
Oct 31, 2025

What analysts say about Larimar Therapeutics Inc ZA71 stockDividend Aristocrats List & Superior Capital Growth - earlytimes.in

Oct 31, 2025
pulisher
Oct 31, 2025

2025-10-31 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Larimar Therapeutics, Inc. (LRMR) And Encourages Shareholders to Reach Out | NDAQ:LRMR | Press Release - Stockhouse

Oct 31, 2025
pulisher
Oct 31, 2025

Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia - MSN

Oct 31, 2025

Finanzdaten der Larimar Therapeutics Inc-Aktie (LRMR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$37.30
price down icon 0.64%
$28.71
price up icon 0.35%
$101.57
price up icon 8.65%
$103.95
price up icon 0.04%
biotechnology ONC
$311.86
price up icon 0.44%
$186.23
price down icon 1.78%
Kapitalisierung:     |  Volumen (24h):